Skip to main content Accessibility help
  • Print publication year: 2014
  • Online publication date: June 2014

4 - Medical management of excessive menstrual bleeding


Management of excessive menstrual bleeding has changed over the past two decades with the promotion of effective medical treatments and in particular the use of the levonorgestrel-releasing intrauterine device. The aims of therapy are to reduce blood loss, reduce the risk of anaemia and improve quality of life. Non-hormonal treatment options for excessive menstrual bleeding are non-steroidal anti-inflammatory drugs, antifibrinolytics, and etamsylate. Intrauterine administration of levonorgestrel, oral and intramuscular progestogens, oestrogen/progestogen combinations, and antiprogestogens are used as hormonal treatments for excessive menstrual bleeding. Plasminogen activator inhibitors have been promoted as a treatment for excessive menstrual bleeding because of increased endometrial fibrinolytic activity in women. The use of progestogens is based on the erroneous concept that women with excessive menstrual bleeding principally have anovulatory cycles and require progestogen supplementation. From clinical experience, combined oral contraceptives (COCs) are generally considered to be effective in the management of dysfunctional menstrual bleeding.

Related content

Powered by UNSILO


1. Hospital episode statistics (HES) online. Main procedures and interventions: 3 character [].
2. National Institute for Health and Clinical Excellence. Heavy Menstrual Bleeding: Investigation and Treatment. Clinical guideline 44. London; NICE: 2007 [].
3. OehlerMK, ReesMC. Menorrhagia: an update. Acta Obstet Gynecol Scand 2003;82:405–22.
4. NHS Evidence. Clinical Knowledge Summaries: Menorrhagia [].
6. LethabyA, AugoodC, DuckittK, FarquharC. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(4):CD000400.
7. LethabyA, FarquharC, CookeI. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;CD000249.
8. NaoulouB, TsaiMC. Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: A systematic review. Acta Obstet Gynecol Scand. 2012 Jan 10. doi: 10.1111/j.1600–0412.2012.01361.x. [Epub ahead of print].
9. LethabyAE, CookeI, ReesM. Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005;(4):CD002126.
10. LethabyA, IrvineG, CameronI. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008;(1):CD001016.
11. RobertsTE, TsourapasA, MiddletonLJ. Hysterectomy, endometrial ablation, and levonorgestrel releasing intrauterine system (Mirena) for treatment of heavy menstrual bleeding: cost effectiveness analysis. BMJ 2011;342:d2202.
12. BhattacharyaS, MiddletonLJ, TsourapasA, et al.; International Heavy Menstrual Bleeding Individual Patient Data Meta-analysis Collaborative Group. Hysterectomy, endometrial ablation and Mirena® for heavy menstrual bleeding: a systematic review of clinical effectiveness and cost-effectiveness analysis. Health Technol Assess 2011;15:iii–xvi, 1–252.
13. KaunitzAM, MeredithS, InkiP, KubbaA, Sanchez-RamosL. Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstet Gynecol 2009;113:1104–16.
14. WildemeerschD. Intrauterine drug delivery for contraception and gynaecological treatment: novel approaches. Handb Exp Pharmacol 2010;197:267–98.
15. HurskainenR, TeperiJ, RissanenP, et al. Clinical outcomes and costs with the levonorgestrel-releasing intrauterine system or hysterectomy for treatment of menorrhagia: randomized trial 5-year follow-up. JAMA 2004;291:1456–63.
16. LeminenH, Heliövaara-PeippoS, HalmesmäkiK, et al. The effect of hysterectomy or levonorgestrel-releasing intrauterine system on premenstrual symptoms in women treated for menorrhagia: secondary analysis of a randomised controlled trial. Acta Obstet Gynecol Scand 2012;91:279–400.
17. VasilakisC, JickH, del Mar Melero-MontesM. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999;354:1610–11.
18. MaguireK, WesthoffC. The state of hormonal contraception today: established and emerging noncontraceptive health benefits. Am J Obstet Gynecol 2011;205(4 Suppl):S4–8.
19. MicksE, JensenJT. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Womens Health (Lond Engl) 2011;7:513–24.
20. BeaumontH, AugoodC, DuckittK, LethabyA. Danazol for heavy menstrual bleeding. Cochrane Database Syst Rev 2007;(3):CD001017.
21. BrownA, ChengL, LinS, BairdDT. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation: a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J Clin Endocrinol Metab 2002;87:63–70.
22. EisingerSH, BonfiglioT, FiscellaK, MeldrumS, GuzickDS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Minim Invasive Gynecol 2005;12:227–33.
23. WilkensJ, ChwaliszK, HanC, et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity, and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664–71.
24. DonnezJ, TatarchukTF, BouchardP, et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012;366:409–20.
25. DonnezJ, TomaszewskiJ, VázquezF, et al.; PEARL II Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012;366:421–32.
26. KennedyAD, SculpherMJ, CoulterA, DwyerN, ReesM, AbramsKR, et al. Effects of decision aids for menorrhagia on treatment choices, health outcomes, and costs: a randomized controlled trial. JAMA 2002;288:2701–8.